Pfizer’s Biosimilars Top $2.3bn In 2021

Biosimilars Business Expands By Over 50%; Sterile Injectables Grow To $5.7bn

 
• By Akriti Seth
  
Growth
Pfizer’s biosimilars business sees double-digit growth • Source: Alamy

More from Biosimilars

More from Products